Obulytix develops Precision Lysin Therapeutics (PLTs), a new class of targeted biologics designed as next-generation antibiotics. These engineered treatments selectively eliminate bacteria while actively avoiding the development of antimicrobial resistance (AMR). The company provides innovative solutions to combat multidrug-resistant strains and safeguard modern medical capabilities.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of extensively drug-resistant Gram-negative bacteria poses a critical threat, particularly to patients in intensive care units, as regular antibiotics lose their efficacy. This antimicrobial resistance crisis necessitates the development of novel therapeutics to combat life-threatening infections.
Solution
Obulytix is developing a new class of phage lysin-based antibiotics designed to target extensively drug-resistant Gram-negative bacteria. Their proprietary technology platform adapts the hit-to-lead process from drug discovery to the domain of phage lysin-based antibiotics. The platform leverages a VersaTile method and artificial intelligence to efficiently tailor phage lysins into antimicrobials that can eradicate harmful bacteria. Phage lysins degrade bacterial cell walls, killing bacteria rapidly, and offer advantages such as specificity and reduced resistance development.
Target Audience
The primary target audience includes patients in intensive care units facing critical medical conditions due to extensively drug-resistant Gram-negative bacterial infections.
Features
- Proprietary VersaTile method for tailoring phage lysins
- AI-enhanced hit-to-lead process for efficient lysin development
- Focus on extensively drug-resistant Gram-negative bacteria
- Enzyme-based mechanism of action that degrades bacterial cell walls
- Specificity reduces off-target effects
- Potential to combat chronic infections